Nuestro blog

As decentralized trials scale, central rating workflows must keep pace. Here's a clear look at what central rating is, where it fits in trial operations, and why integrated platform delivery is changing the way sponsors manage independent endpoint review.

The conversation at SCOPE 2026 wasn't about what's possible in clinical trials — it was about why it's still so hard to execute. Here's what we heard on the ground.

Discover how simplifying vaccine logistics can make scientific breakthroughs truly global — and why digital innovation is the missing link in equitable access.

The FDA and OHRP have released new draft guidance providing recommendations for making the informed consent process as clear and comprehensive as possible for participants. Here's what you need to know.

Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.

The challenges associated with conducting central nervous system clinical research all impact sponsors’ and study teams’ ability to gather stronger therapeutic evidence—but they also prime CNS studies for decentralization.

Many clinical trial sponsors don’t understand how decentralized clinical trials (DCTs) fit within today’s regulatory landscape. This lack of familiarity with decentralized research and regulatory approaches has created DCT hesitancy among sponsors.

Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.

Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.